Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C.

@article{Bronowicki2014RandomizedTO,
  title={Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C.},
  author={J P Bronowicki and Vlad Ratziu and Adri{\'a}n Carlos Gadano and Paul Joseph Thuluvath and Fernando O Bessone and Claudia T Martorell and Stanislas Pol and Ruben A Terg and Ziad Younes and Bing He and Timothy Eley and David Cohen and Fei Yu and Dennis Hernandez and Fiona Mcphee and P. Mendez and Eric A. Hughes},
  journal={Journal of hepatology},
  year={2014},
  volume={61 6},
  pages={1220-7}
}
BACKGROUND & AIMS Asunaprevir is a selective HCV NS3 protease inhibitor, active against genotypes 1, 4, 5, and 6 in vitro. We evaluated asunaprevir plus peginterferon alfa-2a/ribavirin (PegIFNα/RBV) for genotype 1 and 4 chronic HCV. METHODS In this phase 2b, double-blind, placebo-controlled study, treatment-naive adults with genotype 1 (n=213) or 4 (n=25) were randomly assigned (3:1) to asunaprevir 200mg or placebo twice daily plus PegIFNα/RBV. Asunaprevir recipients, achieving protocol… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 16 references

All-oral therapy with daclatasvir in combination with asunaprevir and BMS-791325 for treatment-naive patients with chronic HCV genotype 4 infection

  • T Hassanein, K Sims, M Bennett, N Gitlin, E Lawitz, T Nguyen
  • J Hepatol 2014;60:S472
  • 2014
3 Excerpts

Hepatitis C viral evolution in genotype 1 treatment-naïve and treatmentexperienced patients receiving telaprevir-based therapy in clinical trials

  • TL Kieffer, S De Meyer, DJ Bartels, JC Sullivan, EZ Zhang, A Tigges
  • PLoS One 2012;7:e34372
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…